STOCK TITAN
  1. Home
  2. News
  3. KZIA

Kazia Therapeutics Limited American Depositary Shares - KZIA STOCK NEWS

Welcome to our dedicated page for Kazia Therapeutics American Depositary Shares news (Ticker: KZIA), a resource for investors and traders seeking the latest updates and insights on Kazia Therapeutics American Depositary Shares stock.

Kazia Therapeutics Limited (NASDAQ: KZIA) is an innovative biotechnology company focused on oncology, based in Sydney, Australia. The company is dedicated to developing cutting-edge anti-cancer drugs, with a robust pipeline aimed at addressing various forms of cancer.

The lead program for Kazia is paxalisib, an investigational brain-penetrant inhibitor of the PI3K / Akt / mTOR pathway. Paxalisib is primarily developed for treating glioblastoma multiforme, a highly aggressive brain cancer. Licensed from Genentech in late 2016, paxalisib has been the subject of numerous clinical trials. A Phase II study reported promising clinical activity, and the drug is currently undergoing pivotal trials, with additional studies targeting brain metastases and other central nervous system (CNS) cancers.

Besides paxalisib, Kazia is advancing EVT801, a small-molecule VEGFR3 inhibitor, licensed from Evotec SE in April 2021. EVT801 has shown preclinical efficacy across a range of tumor types and synergy with immuno-oncology agents. It's currently in Phase I clinical trials for advanced solid tumors.

Another notable drug in Kazia’s pipeline is Cantrixil (TRXE-002-1), under development for ovarian cancer and in Phase I clinical trials in Australia and the United States.

Kazia’s commitment to innovation and collaboration is evident through strategic partnerships and licensing agreements. For example, they recently signed a non-binding Letter of Intent with a biotechnology company to develop and commercialize paxalisib outside oncology, targeting epilepsy related to focal cortical dysplasia type 2 and tuberous sclerosis complex.

Financially, Kazia remains focused on securing funding to sustain its research and development endeavors. The company recently announced a direct offering expected to generate approximately $2 million.

Additionally, Kazia's forward-looking strategy includes addressing market listing requirements and ensuring compliance with Nasdaq’s Minimum Bid Price Requirement.

For more information, visit www.kaziatherapeutics.com or follow them on Twitter @KaziaTx.

News

Kazia announces presentation of new data at AACR Annual Meeting

Rhea-AI Summary
Kazia Therapeutics (KZIA) presents new data on pipeline molecules at AACR, showing promising results for EVT801 and paxalisib in cancer treatment. The data includes phase 1 study results and combination therapy efficacy for atypical teratoid/rhabdoid tumors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.76%
Tags
none
-
News

Kazia Therapeutics Reports Early Conclusion of Clinical Trial After Reaching Primary Endpoint

Rhea-AI Summary
Kazia Therapeutics Limited announces positive results from a Phase I trial combining paxalisib with radiation therapy for treating patients with PI3K pathway mutation brain metastases. The study shows promising safety and clinical activity, with the primary endpoint achieved.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-20%
Tags
clinical trial
-
News

KAZIA CONTINUES BOARD RENEWAL WITH TWO NEW APPOINTMENTS

Rhea-AI Summary
Kazia Therapeutics (KZIA) appoints pharma industry executive Robert Apple as Non-Executive Director and Bryce Carmine as Chairman. Mr. Apple brings over 25 years of leadership experience, including roles at Antares Pharma and InKine Pharmaceutical. Mr. Carmine has a distinguished career at Eli Lilly & Co. CEO Dr. John Friend expressed delight with the appointments, emphasizing the value of their expertise for the company's growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News

Kazia Therapeutics Announces Closing of $2 Million Registered Direct Offering

Rhea-AI Summary
Kazia Therapeutics Limited (NASDAQ: KZIA) closed a purchase and sale of up to 4,444,445 of the Company's American Depositary Shares (ADSs) at a purchase price of $0.45 per ADS, raising approximately $2 million in gross proceeds. The Company also issued unregistered warrants to purchase up to 4,444,445 ADSs at an exercise price of $0.583 per ADS, with H.C. Wainwright & Co. acting as the exclusive placement agent.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.35%
Tags
offering
-
News

Kazia Therapeutics Announces $2 Million Registered Direct Offering

Rhea-AI Summary
Kazia Therapeutics Limited (NASDAQ: KZIA) announced a registered direct offering and a concurrent private placement for the purchase and sale of up to 4,444,445 of the Company's American Depositary Shares at a purchase price of $0.45 per ADS, along with unregistered warrants to purchase up to 4,444,445 ADSs with an exercise price of $0.583 per ADS.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-19.64%
Tags
offering
-
News

KAZIA ANNOUNCES NON-BINDING LETTER OF INTENT FOR THE PROPOSED GRANTING OF RIGHTS TO DEVELOP AND COMMERCIALIZE PAXALISIB OUTSIDE OF ONCOLOGY

Rhea-AI Summary
Kazia Therapeutics Limited (NASDAQ: KZIA) has signed a non-binding Letter of Intent with an undisclosed biotechnology company for the license of worldwide rights, other than mainland China, Hong Kong, Macao, and Taiwan, to develop and commercialize a pharmaceutical product containing paxalisib in an indication outside of cancer. The proposed terms include an upfront payment, potential clinical and regulatory milestone payments, as well as commercial sales-based royalties and milestones. The companies are currently negotiating the definitive license agreement.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.25%
Tags
none
News

KAZIA PROVIDES OVERVIEW OF PAXALISIB RELATED PRESENTATIONS FROM THE SOCIETY OF NEURO-ONCOLOGY 2023 ANNUAL MEETING

Rhea-AI Summary
Kazia Therapeutics Limited (KZIA) provided key highlights of the clinical and preclinical paxalisib related presentations at the Society of Neuro-Oncology 2023 Annual Meeting. The preliminary overall survival data from the PNOC022 clinical study is encouraging, showing potential as an alternative to current standard therapies. Notable findings from the presentations include the combination of ONC201 and paxalisib in treating diffuse midline glioma, exploiting the genetic dependency on PI3K/mTOR signaling for the treatment of H3-altered Diffuse Midline Glioma, and the Phase I study of paxalisib and radiotherapy for CNS disease harboring PI3K pathway mutations. The company has expanded the study after identifying the maximal tolerated dose and observed signals of clinical activity, and they are also exploring the use of plasma circulating tumor DNA as a biomarker to assess patient treatment response. The PNOC022 trial, using an adaptive platform design for patients with diffuse midline gliomas, has enrolled 137 patients across three cohorts with preliminary analyses showing promising median overall survival and progression-free survival rates.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.39%
Tags
none
-
News

KAZIA ANNOUNCES RECEIPT OF NASDAQ MINIMUM BID NOTIFICATION

Rhea-AI Summary
Kazia Therapeutics Limited (NASDAQ: KZIA) received a deficiency notification from Nasdaq, stating non-compliance with the minimum bid price requirement. The company has 180 days to regain compliance, during which its securities will continue to trade as normal on Nasdaq-CM under the ticker KZIA.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.39%
Tags
none
-
News

KAZIA ANNOUNCES THE RELEASE OF PNOC022 CLINICAL STUDY ABSTRACT HIGHLIGHTING PAXALISIB IN DIFFUSE MIDLINE GLIOMA PATIENTS AHEAD OF THE SOCIETY OF NEURO-ONCOLOGY 2023 ANNUAL MEETING

Rhea-AI Summary
Kazia Therapeutics Limited (NASDAQ: KZIA) announces positive preliminary results from a combination therapy trial for diffuse midline gliomas (DMGs) at the Society of Neuro-Oncology 2023 Annual Meeting. The trial, PNOC022, has shown a median overall survival (OS) of 16.5 months, significantly higher than the standard of care. The study has enrolled 68 patients and has partnered with 29 leading children's cancer centers globally.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.05%
Tags
clinical trial
News

KAZIA ANNOUNCES PUBLICATION IN MOLECULAR CANCER THERAPEUTICS HIGHLIGHTING PAXALISIB PRECLINICAL DATA IN MELANOMA

Rhea-AI Summary
Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA) announces promising preclinical data for paxalisib in the treatment of metastatic melanoma, indicating potential as a therapeutic strategy for BRAF-mutant cutaneous melanoma. The data, published in Molecular Cancer Therapeutics, demonstrates paxalisib's inhibition of melanoma cell growth and positive effects on overall survival in preclinical models.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial

FAQ

What is the current stock price of Kazia Therapeutics American Depositary Shares (KZIA)?

The current stock price of Kazia Therapeutics American Depositary Shares (KZIA) is $3.02 as of December 26, 2024.

What is the market cap of Kazia Therapeutics American Depositary Shares (KZIA)?

The market cap of Kazia Therapeutics American Depositary Shares (KZIA) is approximately 13.0M.

What is Kazia Therapeutics’ primary focus?

Kazia Therapeutics focuses on developing innovative oncology drugs, with their lead program being paxalisib for brain cancer.

What is paxalisib?

Paxalisib is an investigational brain-penetrant inhibitor of the PI3K / Akt / mTOR pathway, developed to treat various forms of brain cancer including glioblastoma.

What stage are paxalisib’s clinical trials in?

Paxalisib has completed Phase II clinical trials with promising results and is currently in pivotal trials and various other studies targeting CNS cancers.

What other drugs are in Kazia’s pipeline?

Kazia is also developing EVT801, a VEGFR3 inhibitor for solid tumors, and Cantrixil, aimed at treating ovarian cancer.

How is Kazia financing its projects?

Kazia is securing funding through direct offerings, such as a recent transaction expected to raise approximately $2 million.

What recent partnerships has Kazia formed?

Kazia has signed a non-binding Letter of Intent to develop and commercialize paxalisib for non-oncology indications like epilepsy.

What are the latest clinical trial developments for EVT801?

EVT801 is currently in Phase I clinical trials targeting advanced solid tumors. Preliminary data has shown favorable immune activity and tumor stabilization.

How does Kazia ensure compliance with Nasdaq’s listing requirements?

Kazia actively monitors its stock performance and considers all available options, including potential changes in ADS to ordinary share ratios, to meet Nasdaq’s Minimum Bid Price Requirement.

What is the significance of Kazia’s licensing agreement with Sovargen Co., Ltd?

The agreement allows Sovargen to develop, manufacture, and commercialize paxalisib for treating epilepsy associated with focal cortical dysplasia type 2 and tuberous sclerosis complex, expanding paxalisib’s potential beyond oncology.

Where can I find more information about Kazia Therapeutics?

For more information, visit Kazia's official website at www.kaziatherapeutics.com or follow them on Twitter @KaziaTx.

Stock KZIA logo
Kazia Therapeutics Limited American Depositary Shares

Nasdaq:KZIA

KZIA Rankings

#5505 Ranked by Market Cap
N/A Ranked by Dividends

KZIA Stock Data

12.98M
4.35M
7.06%
0.56%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
NEW SOUTH WALES 2113